Neuroectodermal Tumors (Neuroectodermal Tumor)

Malignant neoplasms arising in the neuroectoderm, the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems, including some glial cells.

Also Known As:

Networked: 187 relevant articles (4 outcomes, 19 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Melanoma (Melanoma, Malignant)
3.	Sarcoma (Soft Tissue Sarcoma)
4.	Squamous Cell Carcinoma (Epidermoid Carcinoma)
5.	Neuroblastoma

Experts

1.	Cheung, Nai-Kong V: 3 articles (05/2015 - 10/2004)
2.	Frühwald, Michael C: 2 articles (08/2013 - 12/2009)
3.	Hasselblatt, Martin: 2 articles (08/2013 - 12/2009)
4.	Boyd, Marie: 2 articles (09/2011 - 08/2008)
5.	Mairs, Rob J: 2 articles (09/2011 - 08/2008)
6.	Pagnan, Gabriella: 2 articles (01/2010 - 12/2004)
7.	Ponzoni, Mirco: 2 articles (01/2010 - 12/2004)
8.	Pastorino, Fabio: 2 articles (01/2010 - 12/2004)
9.	Gross, Nicole: 2 articles (04/2009 - 04/2009)
10.	Meier, Roland: 2 articles (04/2009 - 04/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Neuroectodermal Tumors:

1.	AntigensIBA 10/01/1993 - "The pattern of CD-34 antigen (human progenitor cell antigen) immunoreactivity was studied within normal nerve, and a variety of nerve sheath and neuroectodermal tumors. " 06/01/1992 - "The distribution of antigen detected by SHB-10 on several cell lines of neuroectodermal tumor and lymphoid malignancy was analysed and a slight difference in their cell surface expression is observed when compared with that by conventional anti-CD10. " 05/01/1991 - "Using this antibody, we have identified and characterized antigens present in a subset of neurons in the CNS and in some neuroectodermal tumor lines. " 08/01/1989 - "Therefore, mAb T-199 seems to detect a unique differentiation antigen on neuroectodermal tumors, coexpressed in low amounts on normal neuroectodermally derived cells and natural killer cells. " 01/01/1983 - "Human monoclonal antibody to a neuroectodermal tumor antigen (OFA-I-2)."
2.	betulinic acidIBA 12/01/2000 - "Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors." 07/01/1999 - "Betulinic acid: a new chemotherapeutic agent in the treatment of neuroectodermal tumors." 01/10/2002 - "These data support further preclinical studies of betulinic acid not confined to melanoma and neuroectodermal tumors independently of p53 status." 01/01/2006 - "Betulinic acid (BA), a pentacyclic triterpene of natural origin, effectively induces apoptosis in neuroectodermal tumors and was recently shown to be a potent trigger of cell death in human leukemia-derived cell lines. " 07/01/2003 - "Betulinic acid, a naturally occurring triterpene found in the bark of the white birch tree, has been demonstrated to induce programmed cell death with melanoma and certain neuroectodermal tumor cells. "
3.	AntibodiesIBA 02/15/1991 - "Ninety-six embryonal neuroectodermal tumors were studied histologically and immunohistologically with a panel of antibodies including glial, neuronal, epithelial, mesodermal, and myelin markers. " 12/01/2012 - "Malignant gastrointestinal neuroectodermal tumor showing overlapped immunophenotype with synovial sarcoma: CD99 and SOX10 antibodies are useful in differential diagnosis." 01/01/1984 - "One of the antibodies produced by these clones reacts with the original cell line, SK-PN-DW, and other more differentiated neuroectodermal tumors such as neuroblastomas and melanomas. " 05/22/2015 - "Ganglioside GD2 is highly expressed on neuroectodermal tumors and an attractive therapeutic target for antibodies that have already shown some clinical efficacy. " 10/01/1990 - "Therefore, anti-L1 and anti-MenB antibodies define differentiation-related antigens that could differentiate between Nbs and other tumors and may prove helpful in diagnosis and understanding of the biological nature of neuroectodermal tumors. "
4.	Interleukin-2 (IL2)IBA 01/01/2000 - "This article summarizes therapeutic efficacy and immune mechanisms involved in targeting interleukin-2 (IL-2) to neuroectodermal tumors using ganglioside GD2-specific antibody-IL-2 fusion protein (ch14.18-IL-2). " 03/01/2002 - "Posttransplant adoptive immunotherapy with interleukin-2 in children suffering from neuroectodermal tumors with poor prognosis."
5.	imatinib (Gleevec)FDA Link 09/01/2004 - "A therapeutic role of STI571 (imatinib mesylate) has been anticipated in patients with c-Kit positive neuroectodermal tumors. " 09/01/2004 - "We examined the efficacy of STI571 to inhibit expansion of c-Kit positive neuroectodermal tumor cell lines in vitro and in a mouse model inoculated with ES (Ewing sarcoma) derived tumor cells, and investigated the molecular mechanism of STI571 action. "
6.	EnzymesIBA 01/01/1972 - "Histochemical studies on selected enzymes of experimental neuroectodermal tumors." 02/01/1984 - "Glycolytic enzymes from human neuroectodermal tumors of childhood." 06/01/1983 - "[Glycolytic enzymes from neuroectodermal tumors of childhood]." 07/01/1973 - "[Oxidative-reductive enzymes and the phenomenon of anaplasia in neuroectodermal tumors (a histochemical study)]." 01/01/1976 - "The weak activity of Krebs cycle enzymes and the relatively strong activity of other oxidoreductases, particularly of lactate dehydrogenase, permits to conclude that glycolysis prevails over oxidative processes in neuroectodermal tumor cells. "
7.	Phosphopyruvate Hydratase (Enolase)IBA 04/01/2001 - "Immunohistochemical studies showed the tumor cells were ectodermal in origin but not endodermal, based on three diagnostic features of neuroectodermal tumors 1) pseudorosette formation noted under light microscopy, 2) finding of a small number of dense core neurosecretory granules on electron microscopy, and 3) positive immunostaining for both neuronal specific enolase and protein gene product 9.5. " 12/15/1988 - "Pretreatment samples from 24 children with neuroectodermal tumors (two ganglioneuromas, 22 neuroblastomas) and from 106 others with various tumors were submitted to the enzymatic determination of the serum neuron-specific enolase (NSE). " 01/01/1990 - "A number of laboratory studies that focus on biologic features such as neurotransmitter synthesis (adrenergic and noradrenergic catecholamines), neurotransmitter enzyme expression (dopamine beta hydroxylase, choline acetyl transferase), cytogenetics (homogeneously staining regions, double minute chromosomes, chromosome 1p deletions), molecular genetics (N-myc oncogene amplification and expression), and immunophenotype (surface epitopes such as HLA antigens and GD2 ganglioside and intracytoplasmic determinants such as neurofilament protein, synaptophysin, chromogranin, and neuron specific enolase) now enable the pathologist to predict clinical course in many cases and to distinguish bona fide neuroblastomas, regardless of age, site, or histologic appearance, from a host of related but distinctly separate neuroectodermal tumor entities with apparent different histogenesis, treatment sensitivity, and prognosis." 02/01/1991 - "We studied two cases of pigmented neuroectodermal tumor of infancy (PNTI) by routine light microscopy and immunohistochemistry on formalin fixed, paraffin embedded tissues using antibodies to HMB-45 "melanoma associated" antigen, S-100 protein, neuron specific enolase (NSE), Leu-7 antigen, chromogranin, epithelial membrane antigen, collagen Type IV, alpha-fetoprotein and muscle-specific actin and to the intermediate filaments cytokeratin (CK), vimentin, desmin and neural filaments. "
8.	Bromodeoxyuridine (BrdU)IBA 01/01/1992 - "Over the past several years, we have performed in situ labeling studies of 502 neuroectodermal tumors with BUdR. " 03/01/1986 - "In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling." 12/01/1986 - "Bromodeoxyuridine (BrdU), 150 to 200 mg/m2, was administered at the time of operation to 20 pediatric patients with neuroectodermal tumors to label tumor cells in the S phase. " 09/01/1986 - "In contrast to neuroectodermal tumors, which show widespread BUdR uptake throughout the tissue and which have different average labeling indices according to their histological type (range less than 1% to 15.2%), the teratoma showed BUdR labeling only in certain areas, indicating fairly organized growth patterns; the labeling indices in these areas ranged from 0.39% to 1.9%." 03/01/1986 - "Thirty-eight patients undergoing surgical removal of neuroectodermal tumors of the central nervous system were given a 1-hour intravenous infusion of bromodeoxyuridine (BUdR), 150 to 200 mg/sq m, to label tumor cells in the deoxyribonucleic acid (DNA) synthesis phase (S-phase). "
9.	Proteins (Proteins, Gene)IBA 05/01/2007 - "We found that each of these proteins is expressed in all histological types and grades of human neuroectodermal tumors examined. " 03/06/1998 - "Mutant p53 may selectively suppress glial specific proteins in pluripotential human neuroectodermal tumor cells." 02/01/1996 - "Neuronal thread proteins (NTP) are a group of immunologically related molecules expressed in brain and neuroectodermal tumor cell lines. " 08/15/1993 - "Characterization of thread proteins expressed in neuroectodermal tumors." 01/15/1998 - "As evidence grows that HCMV interacts with apoptotic signaling due to the interaction of HCMV gene products with cellular proteins of apoptotic pathways, we used human NB cell line UKF-NB-2 persistently infected with HCMV strain AD169 to study the effects of long-term HCMV infection on programmed cell death of neuroectodermal tumor cells. "
10.	Monoclonal AntibodiesIBA 07/01/2001 - "In addition, we compared expression of PGP 9.5 with other accepted markers for neuroectodermal tumors including anti-S-100 protein and NKI/C3 monoclonal antibodies. " 01/01/1986 - "The clinical application of neural cell markers and monoclonal antibodies for the diagnosis, localization, and treatment of neuroectodermal tumors is reviewed." 01/01/1984 - "Neuroectodermal tumor and monoclonal antibodies." 05/01/1985 - "The antigenic heterogeneity of human neuroectodermal tumors defined by both murine and human monoclonal antibodies (MAs) is reported; no patterns of reactivity defining degree of anaplasia, in vitro morphology, or immunogen used were apparent. " 01/01/1989 - "We have identified and partially characterized 5 new monoclonal antibodies generated against malignant astrocytoma, medulloblastoma, neuroblastoma and melanoma which were used to define 5 neuroectodermal tumor antigenic systems. "

Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation) 11/01/1991 - "The 3'-isoLM1 and 3',6'-isoLD1 distribution in cultured cell lines and derived xenografts of primary tumors of the human central nervous system and of embryonal or neuroectodermal tumor derivation was determined. " 04/01/2014 - "The findings suggest specific advantages over xenotransplantation and lead us to propose that transplantation to the human embryonic microenvironment in experimental teratoma can be a well-needed complement for preclinical in vivo studies of childhood neuroectodermal tumors. "
2.	Transplantation (Transplant Recipients) 04/01/2014 - "Tropism of the in situ growth from biopsies of childhood neuroectodermal tumors following transplantation into experimental teratoma." 01/01/1993 - "Introduction into fetal rat brain cells of a replication-defective retroviral vector harboring v-Ha-ras and v-gag-myc rapidly causes the induction of highly malignant undifferentiated neuroectodermal tumors following transplantation into the brains of syngeneic hosts [Wiestler, et al. (1992) Cancer Res. 52: 3760-3767]. " 04/01/2014 - "The findings suggest specific advantages over xenotransplantation and lead us to propose that transplantation to the human embryonic microenvironment in experimental teratoma can be a well-needed complement for preclinical in vivo studies of childhood neuroectodermal tumors. "
3.	Intravenous Infusions 01/01/1994 - "Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors." 03/01/1986 - "Thirty-eight patients undergoing surgical removal of neuroectodermal tumors of the central nervous system were given a 1-hour intravenous infusion of bromodeoxyuridine (BUdR), 150 to 200 mg/sq m, to label tumor cells in the deoxyribonucleic acid (DNA) synthesis phase (S-phase). "
4.	Immunotherapy 01/01/2011 - "The present study evidenced the expression of NeuGc-GM3 in a high proportion of neuroectodermal tumors, suggesting its potential utility as a specific target of immunotherapy." 12/15/2012 - "The ganglioside GD2 is an attractive target for immunotherapy of neuroectodermal tumors. "
5.	Drug Therapy (Chemotherapy) 02/01/2000 - "Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli." 06/01/1985 - "Measurements of in vivo 31P nuclear magnetic resonance spectra in neuroectodermal tumors for the evaluation of the effects of chemotherapy." 02/01/2000 - "The natural history of neuroectodermal tumors is still debated as far as prognostic factors are concerned; the same uncertainty applies to the optimal radiotherapy schedule and even more to the presumptive additive effect of chemotherapy. " 07/01/2003 - "Because some of these rare tumors are sensitive to chemotherapy, their recognition and separation from other neuroectodermal tumors are advisable for better understanding of their biology and determination of optimal treatment." 09/01/1994 - "A 2 year-old boy was admitted because he had developed fever and neutropenia during chemotherapy given for neuroectodermal tumor. "